How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,819 results for

Renin-Angiotensin System

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. The tissue renin-angiotensin system (tRAS) and the impact of its inhibition on inflammation and bone loss in the periodontal tissue: A systematic review and network meta-analysis of animal studies

The tissue renin-angiotensin system (tRAS) and the impact of its inhibition on inflammation and bone loss in the periodontal tissue: A systematic review and network meta-analysis of animal studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2020 PROSPERO

142. Renin-angiotensin-aldosterone system (RAAS) inhibitor use and COVID-19 disease severity

Renin-angiotensin-aldosterone system (RAAS) inhibitor use and COVID-19 disease severity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

143. Renin-angiotensin-aldosterone system (RAAS) inhibitors and COVID-19 mortality in patients with hypertension hospitalized for COVID-19: a systematic review and meta-analysis

Renin-angiotensin-aldosterone system (RAAS) inhibitors and COVID-19 mortality in patients with hypertension hospitalized for COVID-19: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

144. Impact of renin-angiotensin-aldosterone system inhibitors on mortality in hypertensive patients with COVID-19: systematic review and meta-analysis

Impact of renin-angiotensin-aldosterone system inhibitors on mortality in hypertensive patients with COVID-19: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

145. Efficacy of renin-angiotensin system inhibitors on the severity and risk of death in patients with hypertension for coronavirus disease 2019 (covid-19): a systematic review and meta-analysis

Efficacy of renin-angiotensin system inhibitors on the severity and risk of death in patients with hypertension for coronavirus disease 2019 (covid-19): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2020 PROSPERO

146. A systematic review and meta-analysis of observational studies on the safety of renin-angiotensin system (RAS) blockers (angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs)) in relation to the likelihood of infection wi

A systematic review and meta-analysis of observational studies on the safety of renin-angiotensin system (RAS) blockers (angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs)) in relation to the likelihood of infection wi Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2020 PROSPERO

147. Traumatic brain injury and drugs acting on the renin angiotensin system as potential treatment: a systematic review

Traumatic brain injury and drugs acting on the renin angiotensin system as potential treatment: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

148. Use of renin-angiotensin-aldosterone system inhibitors and risks of COVID-19

Use of renin-angiotensin-aldosterone system inhibitors and risks of COVID-19 Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2020 PROSPERO

149. Renin Angiotensin System in Women Using Combined Oral Contraceptives

Renin Angiotensin System in Women Using Combined Oral Contraceptives Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2020 PROSPERO

150. Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function?new warnings

Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function?new warnings Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Combination use of medicines from different classes of renin-angiotensin system (...) blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings New warnings due to risk of hyperkalaemia, hypotension, and impaired renal function have been agreed following an EU-wide review. Published 11 December 2014 From: Therapeutic area: , , Contents Article date: June 2014 The renin-angiotensin hormone system (RAS) controls blood pressure and the volume of fluids in the body. Medicines that have an inhibitory action on the RAS (RAS blocking agents) are used

2014 MHRA Drug Safety Update

151. Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. Full Text available with Trip Pro

Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs. This study sought to evaluate the therapeutic effects of renal denervation (RDN) on acute myocardial infarction (MI) in canines and explore its possible mechanisms of action.Eighteen healthy mongrel dogs were randomly assigned to either the control group, the MI group or the MI + RDN group. To assess cardiac function, left (...) ) and activity of superoxide dismutase (SOD). To measure the local activity of the sympathetic nervous system (SNS) and renin-angiotensin system (RAS), the levels of tyrosine hydroxylase (TH), angiotensin II (AngII), angiotensin-converting enzyme 2 (ACE2), angiotensin (1-7) [Ang(1-7)] and Mas receptor (MasR) in myocardial tissues were recorded. The expression of TH in renal tissue and serum creatinine were used to assess the effectiveness of the RDN procedure and renal function, respectively.We found that MI

2017 BMC Cardiovascular Disorders

152. Cohort study: Renin-angiotensin system blockers increase risk of angio-oedema

Cohort study: Renin-angiotensin system blockers increase risk of angio-oedema Renin-angiotensin system blockers increase risk of angio-oedema | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Renin-angiotensin system blockers increase risk of angio-oedema Article Text Aetiology Cohort study Renin-angiotensin system blockers increase risk of angio-oedema Massimo Volpe , Giuliano Tocci Statistics from Altmetric.com Commentary on: Toh S

2013 Evidence-Based Medicine

153. Cohort study: Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction

Cohort study: Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved

2013 Evidence-Based Medicine

154. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. Full Text available with Trip Pro

Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function.To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR.Retrospective cohort

2018 JAMA

155. Understanding the Renin-Angiotensin-Aldosterone-SARS-CoV-Axis: A Comprehensive Review. Full Text available with Trip Pro

morbidity and mortality is narrow but remains open. The renin-angiotensin-aldosterone system (RAAS) is crucial to the homeostasis of both the cardiovascular and respiratory systems. Importantly, SARS-CoV-2 utilises and interrupts this pathway directly, which could be described as the renin-angiotensin-aldosterone-SARS-CoV-2-axis (RAAS-SCoV-axis). There exists significant controversy and confusion surrounding how anti-hypertensive agents might function along this pathway. This review explores the current (...) Understanding the Renin-Angiotensin-Aldosterone-SARS-CoV-Axis: A Comprehensive Review. Coronavirus Disease 19 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic with significant morbidity and mortality since first appearing in Wuhan, China, in late 2019. As many countries are grappling with the onset of their epidemics, pharmacotherapeutics remain lacking. The window of opportunity to mitigate downstream

2020 European Respiratory Journal

156. Association of renin-angiotensin system genetic polymorphisms and aneurysmal subarachnoid hemorrhage. (Abstract)

Association of renin-angiotensin system genetic polymorphisms and aneurysmal subarachnoid hemorrhage. OBJECTIVE Renin-angiotensin system (RAS) genetic polymorphisms are thought to play a role in cerebral aneurysm formation and rupture. The Cerebral Aneurysm Renin-Angiotensin System (CARAS) study prospectively evaluated common RAS polymorphisms and their relation to aneurysmal subarachnoid hemorrhage (aSAH). METHODS The CARAS study prospectively enrolled aSAH patients and controls at 2 academic

2017 Journal of Neurosurgery

157. Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study. Full Text available with Trip Pro

Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study. The potential protective effect of renin-angiotensin system (RAS) inhibitors is a subject of increasing interest due to their possible role as chemopreventive agents against colorectal cancer (CRC). To evaluate this association, we conducted a case-control study with 2165 cases of colorectal cancer, diagnosed between 2007 and 2012, and 3912 population controls frequency matched (by age

2017 Preventive Medicine

158. Skeletal muscle wasting: new role of nonclassical renin-angiotensin system. (Abstract)

Skeletal muscle wasting: new role of nonclassical renin-angiotensin system. Skeletal muscle can be affected by many physiological and pathological conditions that contribute to the development of muscle weakness, including skeletal muscle loss, inflammatory processes, or fibrosis. Therefore, research into therapeutic treatment alternatives or alleviation of these effects on skeletal muscle is of great importance.Recent studies have shown that angiotensin (1-7) [Ang-(1-7)] - a vasoactive peptide (...) of the nonclassical axis in the renin-angiotensin system (RAS) - and its Mas receptor are expressed in skeletal muscle. Ang-(1-7), through its Mas receptor, prevents or diminishes deleterious effects induced by skeletal muscle disease or injury. Specifically, the Ang-(1-7)-Mas receptor axis modulates molecular mechanisms involved in muscle mass regulation, such as the ubiquitin proteasome pathway, the insulin-like growth factor type 1/Akt (protein kinase B) pathway, or myonuclear apoptosis, and also inflammation

2017 Current opinion in clinical nutrition and metabolic care

159. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Full Text available with Trip Pro

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Elevated serum aldosterone can be vasculotoxic and facilitate cardiorenal damage. Renin-angiotensin system inhibitors reduce serum aldosterone levels and/or block its effects but can cause hyperkalemia. Patiromer, a nonabsorbed potassium binder, decreases serum potassium in patients with chronic kidney disease on renin-angiotensin system inhibitors (...) . Here we examined the effect of patiromer treatment on serum aldosterone, blood pressure, and albuminuria in patients with chronic kidney disease on renin-angiotensin system inhibitors with hyperkalemia (serum potassium 5.1-6.5 mEq/l). We analyzed data from the phase 3 OPAL-HK study (4-week initial treatment phase of 243 patients; 8-week randomized withdrawal phase of 107 patients). In the treatment phase, the (mean ± standard error) serum potassium was decreased concordantly with the serum

2017 Kidney International Controlled trial quality: uncertain

160. Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS) Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pediatric (...) Primary Hypertension and the Renin-Angiotensin System (PHRAS) (PHRAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03310684 Recruitment Status : Enrolling by invitation First Posted : October 16, 2017 Last Update Posted : December 21, 2018 Sponsor: Wake Forest University Health Sciences Information

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>